Regulations Causing Innovation Failure, Impact Pfizer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulations Causing Innovation Failure, Impact Pfizer


ePT--the Electronic Newsletter of Pharmaceutical Technology

According to the UK’s Economic and Social Research Council (ESRC), the closure of Pfizer’s UK research and development (R&D) facility, announced last week, is part of a long-term decline in drug development that is affecting all major UK pharmaceutical multinationals. The ESRC blames the decline on “failure of innovative drive in the industry, failure of the UK to support basic research, failure of venture capital to invest in early-stage research, or failure of the Health Service to provide smart procurement.”

In particular, the stunted innovation has been attributed to the “lengthy and expensive regulatory system,” according to an ESRC press statement. Although regulation impacts all products developed by any industry sector, it is significantly felt in the pharma industry, where it affects overall company strategies, which companies succeed and fail, and, ultimately, the entire structure and dynamism of the sector as a whole.

According to research by the ESRC’s Innogen Center, the pharmaceutical industry is approaching a “tipping point” in the not-too-distant future in which innovation will no longer be sustainable. However, “radical reform” of regulatory systems could help to better ensure a productive and profitable pharma sector—both globally and in the UK.

“We do not need less regulation, but smarter regulation that can deliver expected standards of safety and efficacy, and that is flexible enough to respond to new scientific discoveries and do so more efficiently than our current systems within a shorter timeframe,” Professor Joyce Tait, director of the ESRC's Innogen Center, said in the statement.

ESRC believes that radical regulatory reform for the life-sciences industries should be a priority in discussions regarding the industry’s future. “Reform could provide the lever to profitably unleash the creativity that has been so effectively generated from public funding of basic science, leading to something closer to the innovative performance that we have seen in information and communication technologies over the past 20 years,” said the ESRC in the press statement.

See a related blog post on PharmTech Talk, titled, Pfizer Site Closure “Shocking Wake-Up Call” for UK

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here